The minimally invasive procedures (mips) for the treatment of symptoms of benign prostatic hyperplasia (bph) are presented as attractive techniques due to their ease of accomplishment and the possibility of outpatient treatment. This guideline aims to present recommendations that may assist in decision making in patients with benign prostatic hyperplasia and indication of the different minimally invasive therapies. For this, a systematic review of the literature was performed, with the descriptors according to the pico: patient with benign prostatic hyperplasia, minimally invasive therapy, clinical outcome and adverse events. With no time restriction, in medline, cochrane central and lilacs databases via vhl, 1,007 papers were retrieved, of which 16 were selected to respond to clinical doubt. Details of the methodology and results of this guideline are set out in annex I.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/1806-9282.64.10.876 | DOI Listing |
Sci Rep
January 2025
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Lower urinary tract symptoms (LUTS) significantly affect patient quality of life. Treatment options for bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) (a common cause of LUTS) are insufficient to relieve discomfort. As the incidence of BPH is increasing, new pharmacological targets for LUTS treatment are required.
View Article and Find Full Text PDFClin Genitourin Cancer
December 2024
Esenler Maternity and Child Diseases Hospital, Department of Urology, Istanbul, Turkey.
Introduction: Bladder cancer is common in men. The number of recurrences is one of the risk factors for progression and poor prognosis in nonmuscle invasive bladder cancer (NMIBC). We aimed to investigate whether bladder outlet obstruction (BOO) has an effect on bladder cancer recurrence in patients with nonmuscle invasive bladder cancer.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
The Second Department of Infectious Disease, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
Background: Erectile dysfunction (ED) is characterized by the inability to achieve or maintain penile erection sufficient for intercourse. While previous research suggests a potential link between ED and prostate pathologies, the association between benign prostatic hyperplasia (BPH), prostatitis, prostatic cancer (PCa), and ED remains to be elucidated.
Methods: Data from participants (40-80 years, n=2225) were extracted from the NHANES 2001-2004 for this observational study.
Res Rep Urol
January 2025
Department of Pathology, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Introduction: Prostate cancer (CaP) is the most common malignancy and the second leading cause of cancer-related deaths among men in Botswana. Currently, diagnosing CaP relies on examining prostate biopsy samples, which can be challenging due to benign mimics. This study aims to evaluate the potential of Alpha-methyl acyl-CoA racemase (AMACR/p504s) and p63, as diagnostic markers for CaP.
View Article and Find Full Text PDFFront Nutr
January 2025
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: Coffee is a physiologically active food component prevalent throughout the world, but the association between caffeine intake and benign prostatic hyperplasia (BPH) has been limited in extensive epidemiological studies.
Methods: We conducted a cross-sectional study to evaluate the association between caffeine intake and BPH in adults in the United States using data from the National Health and Nutrition Examination Survey (NHANES) 2005-2008. Caffeine intake (mg/day) was evaluated based on a 24-h dietary recall.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!